Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SNSE 
Sensei Biotherapeutics Inc (SNSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: SNSE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.45% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.26M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 2 | Beta 0.31 | 52 Weeks Range 5.00 - 18.35 | Updated Date 12/6/2025 |
52 Weeks Range 5.00 - 18.35 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.04% | Return on Equity (TTM) -70.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12046777 | Price to Sales(TTM) - |
Enterprise Value -12046777 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 1261290 | Shares Floating 826851 |
Shares Outstanding 1261290 | Shares Floating 826851 | ||
Percent Insiders 34.26 | Percent Institutions 3.95 |
Upturn AI SWOT
Sensei Biotherapeutics Inc
Company Overview
History and Background
Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of next-generation immunotherapies to treat cancer. Founded in 2011, they are leveraging their ImmunoPhage platform to develop therapies that prime and educate the immune system to attack cancer cells. Early milestones included preclinical validation of their platform and progressing lead candidates into clinical trials. The company has evolved from a research-focused entity to a clinical-stage company with a pipeline of immunotherapy programs.
Core Business Areas
- Immuno-oncology Drug Development: Focuses on developing immunotherapies using its ImmunoPhage platform.
- Preclinical and Clinical Research: Conducts research and clinical trials to advance its drug candidates.
- Platform Technology Licensing: Potentially out-licensing their ImmunoPhage platform technology to other companies.
Leadership and Structure
The leadership team consists of experienced executives in the biopharmaceutical industry, with expertise in drug development, clinical research, and business development. The company likely has a traditional biotech organizational structure, with departments focused on research, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- SNS-301: A conditionally active antibody targeting tumor-associated carbohydrate antigen (TACA) Globo H. It's in early-stage clinical trials. Competitors include companies developing antibody-drug conjugates targeting similar antigens.
- SNS-VISTA: An ImmunoPhage targeting VISTA (V-domain Ig suppressor of T cell activation). It's in preclinical development. Competitors include companies developing VISTA inhibitors.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment within the pharmaceutical industry. It focuses on developing therapies that harness the body's immune system to fight cancer. The market is characterized by high innovation, intense competition, and significant investment. There is great interest in novel targets and approaches to overcome immune suppression in the tumor microenvironment.
Positioning
Sensei Biotherapeutics is positioned as a company focused on next-generation immunotherapies utilizing its ImmunoPhage platform. Their competitive advantage lies in the potential of their platform to generate robust and targeted immune responses against cancer cells.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars in the coming years. Sensei Biotherapeutics is positioned to capture a share of this market by developing innovative therapies that address unmet needs in cancer treatment. Their TAM is dependent on the specific cancer indications their therapies target and their success in clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary ImmunoPhage platform
- Novel immunotherapy approach
- Experienced management team
- Pipeline of preclinical and clinical programs
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Reliance on a single platform
- Uncertainty in clinical trial outcomes
Opportunities
- Partnerships and collaborations
- Expansion into new cancer indications
- Out-licensing of platform technology
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- LLY
Competitive Landscape
Sensei Biotherapeutics faces intense competition from established pharmaceutical companies and other biotechnology firms. Their success will depend on demonstrating superior efficacy and safety compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and clinical progress. The company has likely relied on equity financing to fund its operations.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization efforts. Analyst estimates will vary based on perceived risk and potential of their pipeline.
Recent Initiatives: Recent initiatives may include enrolling patients in clinical trials, presenting data at scientific conferences, and securing partnerships or funding.
Summary
Sensei Biotherapeutics is an early-stage biotech company with a promising ImmunoPhage platform for developing novel immunotherapies. While their technology has potential, they face significant risks associated with clinical development and competition. Success hinges on positive clinical trial outcomes and securing funding to advance their pipeline. They need to look out for competitive threats and the complexities of regulatory approval.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensei Biotherapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-02-04 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.senseibio.com |
Full time employees 14 | Website https://www.senseibio.com | ||
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.